Xspray Pharma (Q4 Review): A pivotal year ahead - Redeye

After a year marked by both progress and setbacks, Xspray enters a pivotal 2026, with two upcoming PDUFA decisions followed by the potential launches of its lead candidates, Dasynoc and XS003. These events constitute high-impact, yet binary, catalysts, and considering Xspray's historical trading patterns ahead of PDUFA, this provides a good setup for the stock in H1 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1146648/xspray-pharma-q4-review-a-pivotal-year-ahead?utm_source=finwire&utm_medium=RSS